Axilläre Dissektion versus Sentinel-Lymphknotenbiopsie - nicht konkurrierende, sondern ergänzende Verfahren in der Therapie des Mammakarzinoms

Zusammenfassung

Die Axilladissektion stellt einen allgemeinen Standard in der operativen Therapie des invasiven Mammakarzinoms dar. Die wichtigsten hierdurch verfolgten Ziele sind die Bestimmung des Lymphknotenstatus, eine Verbesserung der lokoregionären Tumorkontrolle und konsekutiv damit auch des Überlebens der Patienten [1]. Mit der Sentinel-Lymphknoten-Biopsie wird eine Individualisierung der Therapie angestrebt, ohne die Ziele der ALND außer Acht zu lassen [2]. Nachfolgend sollen die Vor- und Nachteile der beiden Vorgehensweisen und deren Einbindungsmöglichkeiten in ein modernes multimodales Konzept aufgezeigt werden.

Abstract

Axillary lymph node dissection (ALND) is a therapeutic standard in the operative therapy of invasive breast cancer. The major goals of ALND are the determination of the nodal status, local tumor control and the potentially resulting improvement of disease-free survival. The introduction of the sentinel lymph node biopsy in the therapeutic concept is one step further into the individualization of therapy without neglecting the goals of ALND. In the following, the advantages of both methods are discussed in the context of an interdisciplinary approach.

Schlüsselwörter

Sentinel Lymphknoten - Axilladissektion - Sentinel Lymphknotenbiopsie - Brustkrebs - Mammakarzinom - multimodale Therapie

Key words

Sentinel lymph node - sentinel lymph node biopsy - breast cancer - carcinoma of the breas - axillary lymph node dissection - interdisciplinary therapy

Literatur

• 1 Bembenek A, Schlag P M. Lymph node dissection in breast cancer.  Langenbeck's Arch Surg. 1999;  385 236-245
• 2 Schlag P M. Sentinel Lymphknoten Biopsie. Landsberg; ecomed Verlagsgesellschaft 2001
• 3 Graversen H P, Blichert-Toft M, Andersen J A, Zedeler K. Danish Breast Cancer Cooperative Group . Breast cancer: risk of axillary recurrence in nodal-negative patients following partitial dissection of the axilla.  Eur J Surg Oncol. 1988;  14 407-412
• 4 International Breast Cancer Study Group . Prognostic importance of occult axillary lymph node micrometastases from breast cancers.  Lancet. 1990;  335 1565-1568
• 5 Cote J R, Peterson H F, Chaiwun P, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer.  Lancet. 1999;  354 896-900
• 6 Turner R R, Ollila D S, Krasne D L, Giuliano A E. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma.  Ann Surg. 1997;  226 271-278
• 7 Chu K U, Turner R R, Hansen N M, Brennan M B, Bilchik A, Giuliano A E. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?.  Ann Surg. 1999;  229 536-541
• 8 van Diest P J, Torrenga H, Meijer S, Meijer C JLM. Pathological analysis of sentinel lymph nodes.  Sem Surg Oncol. 2001;  20 238-245
• 9 Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series.  J Natl Cancer Inst. 1999;  91 368-373
• 10 Bembenek A, Reuhl T, Markwardt J, Schneider U, Schlag P M. Sentinel lymph node dissection in breast cancer.  Swiss Surg. 1999;  5 217-221
• 11 McMasters K M, Wong S L, Chao C, et al. Defining the optimal surgeon experience for breast cancer sentinel lymph nodde biopsy: A model for implementation of new surgical techniques.  Ann Surg. 2001;  234 292-300
• 12 Van der Ent F WC, Kengen R AM, Van der Pool H AG, Povel J AC, Stroeken H JG, Hoofwijk A GM. Halsted revisited: Internal mammary sentinel lymph node Biopsy in breast cancer.  Ann Surg. 2001;  234 79-84
• 13 Byrd D B, Dunnwald L K, Mankoff D A, et al. Internal mammary lymph node drainage patterns in patients with breast cancer documented by lymphscintigraphy.  Ann Surg Oncol. 2001;  8 234-240
• 14 Borgstein P J, Meijer S, Pijpers R J, van Diest P J. Functional lymphatic anatomy for sentinel node biopsy in breast cancer. Echoes from the past and the periareolar blue method.  Ann Surg. 2000;  232 81-89
• 15 Fischer B, Redmond C, Fisher E R, et al. Ten-year results of a randomized clinical trial comapring radical mastectomy and total mastectomy with or without radiation.  N Engl J Med. 1985;  312 674-681
• 16 Osborne M P, Ormiston N, Harmer C L, McKinna J A, Baker J, Greening P. Breast conservation in the treatment of early breast cancer.  Cancer. 1984;  53 349-355
• 17 Orr R K. The impact of prophylactic axillary node dissection on breast cancer survival - a Bayesian meta-analysis.  Ann Surg Oncol. 1999;  6 109-116
• 18 Bland K I, Scott-Conner C E, Menck H, Winchester D P. Axillary dissection in breast-conserving surgery for stage I and II breast cancer: A national cancer data base study of patterns of commission and implications for survival.  J Am Coll Surg. 1999;  188 586-596
• 19 Shetty M R, Reiman H M. Tumor size and axillary metastases, a correlation occurrence in 1244 cases of breast cancer between 1980 and 1995.  Eur J Surg Oncol. 1997;  23 139-141
• 20 Ververs J M, Roumen R M, Vingerhoets A J, Vreugdenhil G, Coebergh J W, Crommelin M A, Luiten E J, Repelaer van Driel O J, Schijven M, Wissing J C, Voogd A C. Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer.  Europ J Cancer. 2001;  37 (8) 991-999
• 21 Petrek J A, Senie R T, Peters M, Rosen P P. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis.  Cancer. 2001;  92 (6) 1368-1377
• 22 Kuehn T, Vogl F D, Pueckler S, et al. Sentinel node biopsy in breast cancer - technical performance is more important than patient selection to avoid false-negative findings.  Eur J Cancer. 2001;  37 Abstract 994
• 23 Sener S F, Winchester D J, Martz C H, et al. Lymphedema after sentinel lymphadenectomy for breast carcinoma.  Cancer. 2001;  92 748-752
• 24 Early Breast Cancer Trialists Collaborative Group . Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer.  N Engl J Med. 1988;  319 1681-1692
• 25 Dees E C, Shulman L N, Souba W W, Smith B L. Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer?.  Ann Surg. 1997;  226 279-287
• 26 Goldhirsch A, Glick J H, Gelber R D, Senn H J. International consensus panel on the treatment of primary breast cancer: V: update 1998.  Rec Res Cancer Res. 1998;  152 481-497
• 27 Goldhirsch A, Glick J H, Gelber R D, Coates A S, Senn H J. Meeting highlights: International Consensus Panel on the treatment of primary Brest cancer: Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.  J Clin Oncol. 2001;  19 3817-3827
• 28 Levine M N, Bramwell V H, Pritchard K I, Norris B D, Shepherd L E, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Ottaway J, Burnell M, Williams C K, Tu D. Randomized trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer: National Cancer Institute of Canada Clinical Trials Group.  J Clin Oncol. 1998;  16 (8) 2651-2658
• 29 Goldhirsch A, Francis P, Castiglione-Gertsch M, Gelber R D, Coates A S. Taxanes as adjuvant for breast cancer.  Lancet. 2000;  356 (9228) 507-508
• 30 Ragaz J, Jackson S M, Plenderleith I H, Spinelli J J, Basco V E, Wilson K S, Knowling M A, Coppin C ML, Paradis M, Coldman A J, Olivotto I A. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.  New Engl J Med. 1997;  337 956-962
• 31 Dowlatsahi K, Fan M, Anderson J M, Bloem K J. Occult metastases in sentinel nodes of 200 patients with operable breast cancer.  Ann Surg Oncol. 2001;  8 675-682
• 32 Ross M I. Sentinel node dissection in early-stage breast cancer: Ongoing prospective randomized trials in the USA.  Ann Surg Oncol. 2001;  8 77-81